LY293111 – 5 mg

Brand:
Cayman
CAS:
161172-51-6
Storage:
-20
UN-No:
De Minimis - 1231 / 3

Leukotriene B4 (LTB4) is a dihydroxy fatty acid derived from the 5-lipoxygenase pathway of arachidonic acid metabolism and is an important mediator of the inflammatory process. LY293111 is a potent antagonist of the leukotriene B4 (LTB4) receptor, BLT1, that inhibits the specific binding of radiolabeled-LTB4 to isolated human neutrophils with an IC50 value of 17.6 nM and inhibits the LTB4-induced chemotaxis of human neutrophils with an IC50 value of 6.3 nM.{14782} LY293111 inhibits growth of MiaPaCa-2 and AsPC-1 human pancreatic cancer cells in vitro (250-1,000 nM) and subcutaneous xenografts in athymic mice (250 mg/kg/day), inducing apoptosis and S-phase arrest.{16702}  

 

Available on backorder

SKU: 10009768 - 5 mg Category:

Description

A potent antagonist of the LTB4 receptor, BLT1, that inhibits the specific binding of radiolabeled LTB4 to isolated human neutrophils (IC50 value of 17.6 nM); inhibits the LTB4-induced chemotaxis of human neutrophils (IC50 value of 6.3 nM)


Formal name: 2-[3-[3-[(5-ethyl-4′-fluoro-2-hydroxy[1,1′-biphenyl]4-yl)oxy]propoxy]-2-propylphenoxy]-benzoic acid

Synonyms:  Etalocib|VML 295

Molecular weight: 544.6

CAS: 161172-51-6

Purity: ≥98%

Formulation: A solution in methyl acetate


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cancer|Cell Cycle|G2/S||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Lipid Biochemistry|Lipoxygenase Pathways